{"id":"https://openalex.org/W7225636635","doi":"https://doi.org/10.1161/circoutcomes.126.014453","title":"Efficacy and Safety of Pelacarsen in Black/African American and Hispanic Participants with Elevated Lipoprotein(a) and Established Atherosclerotic Cardiovascular Disease: The Randomized Controlled Lp(a)FRONTIERS EXPANSION Study","display_name":"Efficacy and Safety of Pelacarsen in Black/African American and Hispanic Participants with Elevated Lipoprotein(a) and Established Atherosclerotic Cardiovascular Disease: The Randomized Controlled Lp(a)FRONTIERS EXPANSION Study","publication_year":2026,"publication_date":"2026-11-09","ids":{"openalex":"https://openalex.org/W7225636635","doi":"https://doi.org/10.1161/circoutcomes.126.014453"},"language":"en","primary_location":{"id":"doi:10.1161/circoutcomes.126.014453","doi":"https://doi.org/10.1161/circoutcomes.126.014453","is_oa":false,"landing_page_url":"https://doi.org/10.1161/circoutcomes.126.014453","pdf_url":null,"source":{"id":"https://openalex.org/S5407055548","display_name":"Circulation Population Health and Outcomes","issn_l":"3068-563X","issn":["3068-563X"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":["medline"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Circulation: Population Health and Outcomes","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5071877865","display_name":"Keith C. Ferdinand","orcid":"https://orcid.org/0000-0003-3338-4410","observed_orcids":["https://orcid.org/0000-0003-3338-4410"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Keith C. Ferdinand","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-3338-4410","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026322684","display_name":"F\u00e1tima Rodr\u00edguez","orcid":"https://orcid.org/0000-0002-5226-0723","observed_orcids":["https://orcid.org/0000-0002-5226-0723"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Fatima Rodriguez","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-5226-0723","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110418046","display_name":"Duccio Baldari","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Duccio Baldari","raw_affiliation_strings":["Cardiology Partners, Palm Beach County, FL"],"raw_orcid":"https://orcid.org/0009-0002-5179-3701","affiliations":[{"raw_affiliation_string":"Cardiology Partners, Palm Beach County, FL","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5161327397","display_name":"James Sullivan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"James Sullivan","raw_affiliation_strings":["Parkway Medical Center, Birmingham, AL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Parkway Medical Center, Birmingham, AL","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042128267","display_name":"Alexis Gutierrez","orcid":"https://orcid.org/0000-0001-7831-485X","observed_orcids":["https://orcid.org/0000-0001-7831-485X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alexis Gutierrez","raw_affiliation_strings":["Inpatient Research Clinic, LLC, Miami Lakes, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Inpatient Research Clinic, LLC, Miami Lakes, FL","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5161311922","display_name":"Subha Venkataraman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Subha Venkataraman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5161331097","display_name":"Kenny Onate-Quiroz","orcid":"https://orcid.org/0009-0005-4352-6322","observed_orcids":["https://orcid.org/0009-0005-4352-6322"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kenny Onate-Quiroz","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0005-4352-6322","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5161321396","display_name":"Hui Cao","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hui Cao","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036914919","display_name":"Wenyue Zhu","orcid":"https://orcid.org/0000-0002-5731-4364","observed_orcids":["https://orcid.org/0000-0002-5731-4364","https://orcid.org/0009-0005-8894-2741"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Wenyue Zhu","raw_affiliation_strings":["Novartis Pharmaceuticals UK Ltd, London, United Kingdom"],"raw_orcid":"https://orcid.org/0000-0002-5731-4364","affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals UK Ltd, London, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5126533958","display_name":"Jing Wang","orcid":"https://orcid.org/0009-0000-8873-1198","observed_orcids":["https://orcid.org/0009-0000-8873-1198"]},"institutions":[{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jing Wang","raw_affiliation_strings":["Novartis Pharmaceuticals Corp, East Hanover, NJ"],"raw_orcid":"https://orcid.org/0009-0000-8873-1198","affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals Corp, East Hanover, NJ","institution_ids":["https://openalex.org/I4210117619"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5022083191","display_name":"Michael David Shapiro","orcid":"https://orcid.org/0000-0002-9071-3287","observed_orcids":["https://orcid.org/0000-0002-9071-3287"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michael D. Shapiro","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-9071-3287","affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":3.7204,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.86978861,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":91,"max":95},"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12955","display_name":"Atherosclerosis and Cardiovascular Diseases","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T13430","display_name":"Lipid metabolism and disorders","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9050999879837036},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.6758999824523926},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6381999850273132},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.6105999946594238},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5489000082015991},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5099999904632568},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.5020999908447266},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.48159998655319214},{"id":"https://openalex.org/C1862650","wikidata":"https://www.wikidata.org/wiki/Q186005","display_name":"Physical therapy","level":1,"score":0.44760000705718994},{"id":"https://openalex.org/C3020255362","wikidata":"https://www.wikidata.org/wiki/Q747883","display_name":"Physical activity","level":2,"score":0.34369999170303345},{"id":"https://openalex.org/C202953159","wikidata":"https://www.wikidata.org/wiki/Q382695","display_name":"Intention-to-treat analysis","level":3,"score":0.33379998803138733},{"id":"https://openalex.org/C3018127138","wikidata":"https://www.wikidata.org/wiki/Q389735","display_name":"Cardiovascular event","level":3,"score":0.32249999046325684},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.32019999623298645},{"id":"https://openalex.org/C2909478654","wikidata":"https://www.wikidata.org/wiki/Q844935","display_name":"Atherosclerotic cardiovascular disease","level":3,"score":0.3192000091075897},{"id":"https://openalex.org/C61470247","wikidata":"https://www.wikidata.org/wiki/Q7229825","display_name":"Population study","level":3,"score":0.2897999882698059},{"id":"https://openalex.org/C61511704","wikidata":"https://www.wikidata.org/wiki/Q1671857","display_name":"Incidence (geometry)","level":2,"score":0.27549999952316284},{"id":"https://openalex.org/C2777895361","wikidata":"https://www.wikidata.org/wiki/Q1758614","display_name":"Longitudinal study","level":2,"score":0.27059999108314514},{"id":"https://openalex.org/C84393581","wikidata":"https://www.wikidata.org/wiki/Q82642","display_name":"Blood pressure","level":2,"score":0.26840001344680786},{"id":"https://openalex.org/C204243189","wikidata":"https://www.wikidata.org/wiki/Q1363085","display_name":"Randomization","level":3,"score":0.2630999982357025},{"id":"https://openalex.org/C205545832","wikidata":"https://www.wikidata.org/wiki/Q17156455","display_name":"Young adult","level":2,"score":0.25940001010894775},{"id":"https://openalex.org/C2987028688","wikidata":"https://www.wikidata.org/wiki/Q49085","display_name":"African american","level":2,"score":0.2581000030040741}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1161/circoutcomes.126.014453","doi":"https://doi.org/10.1161/circoutcomes.126.014453","is_oa":false,"landing_page_url":"https://doi.org/10.1161/circoutcomes.126.014453","pdf_url":null,"source":{"id":"https://openalex.org/S5407055548","display_name":"Circulation Population Health and Outcomes","issn_l":"3068-563X","issn":["3068-563X"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":["medline"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Circulation: Population Health and Outcomes","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":[],"abstract_inverted_index":{"Background:":[0],"Black":[1],"and":[2,18,30,55,66,74,149,158,162,177,201,238,249,261,288],"Hispanic":[3,67,289],"individuals":[4],"may":[5],"experience":[6],"a":[7,45,119],"disproportionate":[8],"burden":[9],"of":[10,57,96,186,234],"lipoprotein(a)":[11],"[Lp(a)]-associated":[12],"atherosclerotic":[13],"cardiovascular":[14,25],"disease":[15],"(ASCVD)":[16],"risk,":[17],"ASCVD-related":[19],"mortality,":[20],"yet":[21],"remain":[22],"underrepresented":[23],"in":[24,36,62,109,231,246,284],"(CV)":[26],"clinical":[27],"trials.":[28],"Efficacy":[29],"safety":[31,56,97],"data":[32],"on":[33],"Lp(a)-targeted":[34,60],"therapies":[35],"these":[37],"populations":[38,291],"are":[39],"limited.":[40],"Methods:":[41],"Lp(a)FRONTIERS":[42],"EXPANSION":[43],"was":[44,107,193,213,280],"randomized,":[46,130],"double-blind,":[47],"phase":[48],"3b,":[49],"placebo-controlled":[50],"trial":[51],"assessing":[52],"the":[53,270],"efficacy":[54],"pelacarsen,":[58,278],"an":[59,222],"therapy,":[61],"US":[63,285],"Black/African":[64,286],"American":[65,287],"participants":[68,128,235],"with":[69,131,199,207,259,264,277],"elevated":[70],"Lp(a)":[71,111,170,187,275],"(\u2265125":[72],"nmol/L)":[73],"ASCVD.":[75],"Eligible":[76],"adults":[77],"were":[78,129,156,172,256],"randomized":[79],"2:1":[80],"to":[81,135,138,188,221,272],"monthly":[82],"subcutaneous":[83],"pelacarsen":[84,161,200,237,260],"80":[85],"mg":[86],"or":[87],"placebo":[88,163],"for":[89,122,160],"12":[90],"months,":[91],"followed":[92],"by":[93,294],"16":[94],"weeks":[95],"follow-up.":[98],"Enrollment":[99],"spanned":[100],"May":[101],"2024\u2212March":[102],"2025.":[103],"The":[104,140],"primary":[105],"endpoint":[106],"change":[108],"log-transformed":[110],"from":[112],"baseline":[113,169,189],"at":[114,190],"Week":[115,191],"52,":[116],"analyzed":[117,133],"using":[118],"mixed":[120],"model":[121],"repeated":[123],"measures.":[124],"Results:":[125],"Overall,":[126],"423":[127],"422":[132],"(282":[134],"pelacarsen;":[136],"140":[137],"placebo).":[139],"population":[141],"comprised":[142],"64.5%":[143],"(n=272)":[144],"Black/non-Hispanic,":[145],"30.1%":[146],"(n=127)":[147],"nonBlack/Hispanic,":[148],"5.5%":[150],"(n=23)":[151],"Black/Hispanic.":[152],"Trial":[153],"completion":[154],"rates":[155],"90.1%":[157],"91.4%":[159],"groups,":[164],"respectively;":[165],"median":[166],"(Q1,":[167],"Q3)":[168],"levels":[171],"232.70":[173],"nmol/L":[174,179],"(165.80,":[175],"301.50)":[176],"219.25":[178],"(166.95,":[180],"293.65).":[181],"Geometric":[182],"mean":[183],"ratio":[184],"(GMR)":[185],"52":[192],"0.14":[194,214],"(95%":[195,203,215],"CI:":[196,204,216],"0.12,":[197],"0.16)":[198],"0.98":[202],"0.80,":[205],"1.20)":[206],"placebo;":[208,242],"GMR":[209],"between":[210],"groups":[211],"(pelacarsen/placebo)":[212],"0.11,":[217],"0.18;":[218],"P<0.0001),":[219],"equivalent":[220],"86%":[223],"placebo-adjusted":[224],"reduction.":[225],"Treatment-emergent":[226],"adverse":[227],"events":[228],"(TEAEs)":[229],"occurred":[230,245],"66.0%":[232],"(n=186)":[233],"receiving":[236,241],"61.4%":[239],"(n=86)":[240],"serious":[243],"TEAEs":[244],"17.0%":[247],"(n=48)":[248],"15.0%":[250],"(n=21),":[251],"respectively.":[252],"TEAE-related":[253],"treatment":[254],"discontinuations":[255],"6.0%":[257],"(n=17)":[258],"3.6%":[262],"(n=5)":[263],"placebo.":[265],"Conclusions:":[266],"This":[267],"study":[268],"is":[269],"first":[271],"demonstrate":[273],"robust":[274],"lowering":[276],"which":[279],"generally":[281],"well":[282],"tolerated,":[283],"participants,":[290],"disproportionately":[292],"impacted":[293],"Lp(a)-associated":[295],"CV":[296],"risk.":[297],"Registration:":[298],"URL:https://clinicaltrials.gov":[299],"Unique":[300],"Identifier:":[301],"NCT06267560":[302]},"counts_by_year":[{"year":2026,"cited_by_count":1}],"updated_date":"2026-11-10T13:44:29.811591","created_date":"2026-11-10T00:00:00"}